IN8bio Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Public

  • Employees
  • 20

Employees

  • Stock Symbol
  • INAB

Stock Symbol

  • Share Price
  • $0.82
  • (As of Friday Closing)

IN8bio General Information

Description

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Contact Information

Website
www.in8bio.com
Formerly Known As
Incysus, Incysus Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Empire State Building 350 5th Avenue
  • Suite 5330
  • New York, NY 10001
  • United States
+1 (646)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Corporate Office
  • Empire State Building 350 5th Avenue
  • Suite 5330
  • New York, NY 10001
  • United States
+1 (646)

IN8bio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

IN8bio Stock Performance

As of 13-Nov-2026, IN8bio’s stock price is $0.82. Its current market cap is $8.87M with 10.8M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.82 $0.82 $0.80 - $2.73 $8.87M 10.8M 42.8K -$1.00

IN8bio Financials Summary

As of 30-Sep-2026, IN8bio has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV (2,667) 15,110 20,114 52,080
Revenue 0 0 0 0
EBITDA (17,846) (17,293) (27,890) (27,368)
Net Income (19,405) (19,440) (30,437) (30,007)
Total Assets 18,695 32,282 20,944 33,709
Total Debt 2,750 2,782 5,030 4,893
Public Fundamental Data provided by Morningstar, Inc. disclaimer

IN8bio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore IN8bio‘s full profile, request access.

Request a free trial

IN8bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of
Biotechnology
New York, NY
20 As of 2026

South San Francisco, CA
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

IN8bio Competitors (14)

One of IN8bio’s 14 competitors is Allogene Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Allogene Therapeutics Formerly VC-backed South San Francisco, CA
Adicet Bio Formerly VC-backed Boston, MA
Kite Pharma Formerly VC-backed Santa Monica, CA
Century Therapeutics Formerly VC-backed Philadelphia, PA
American Gene Technologies Venture Capital-Backed Rockville, MD
You’re viewing 5 of 14 competitors. Get the full list »

IN8bio Patents

IN8bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026006719-A1 Multifunctional molecules and methods of treatment Pending 28-Jun-2024
EP-4820502-A1 Methods of allogeneic hematopoietic stem cell transplantation and cancer treatment Pending 08-Dec-2023
WO-2025122271-A1 Methods of allogeneic hematopoietic stem cell transplantation and cancer treatment Inactive 08-Dec-2023
WO-2025122271-A9 Methods of allogeneic hematopoietic stem cell transplantation and cancer treatment Inactive 08-Dec-2023
EP-4665362-A2 Non-signaling chimeric antigen receptor gamma delta t-cells Pending 17-Feb-2023 C07K16/2803
To view IN8bio’s complete patent history, request access »

IN8bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

IN8bio ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view IN8bio’s complete esg history, request access »

IN8bio FAQs

  • When was IN8bio founded?

    IN8bio was founded in 2016.

  • Where is IN8bio headquartered?

    IN8bio is headquartered in New York, NY.

  • What is the size of IN8bio?

    IN8bio has 20 total employees.

  • What industry is IN8bio in?

    IN8bio’s primary industry is Biotechnology.

  • Is IN8bio a private or public company?

    IN8bio is a Public company.

  • What is IN8bio’s stock symbol?

    The ticker symbol for IN8bio is INAB.

  • What is the current stock price of IN8bio?

    As of 13-Nov-2026 the stock price of IN8bio is $0.82.

  • What is the current market cap of IN8bio?

    The current market capitalization of IN8bio is $8.87M.

  • Who are IN8bio’s competitors?

    Allogene Therapeutics, Adicet Bio, Kite Pharma, Century Therapeutics, and American Gene Technologies are some of the 14 competitors of IN8bio.

  • What is IN8bio’s annual earnings per share (EPS)?

    IN8bio’s EPS for 12 months was -$1.00.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process